Adult T-Cell Leukemia/Lymphoma Clinical Trial
Official title:
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma. Nivolumab is an antibody, which is a type of blood protein that tags infected cells and other harmful agents. Nivolumab works against a protein called programmed cell death (PD)-1 and may help the body destroy cancer cells by helping the immune system to keep fighting cancer.
PRIMARY OBJECTIVES: I. To determine the safety and tolerability of nivolumab for patients with HTLV-associated adult T-cell leukemia lymphoma (ATLL). II. To determine the efficacy of nivolumab for patients with HTLV-associated ATLL. SECONDARY OBJECTIVES: I. To determine effects of nivolumab on HTLV-1 proviral deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) loads. II. To determine the effects of nivolumab on anti-HTLV-1 and anti-ATLL immune responses. III. To determine effects of nivolumab on HTLV-1 integration site clonality. OUTLINE: Patients receive nivolumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03264131 -
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
|
Phase 2 | |
| Withdrawn |
NCT05321940 -
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
|
Phase 1 | |
| Withdrawn |
NCT04639843 -
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04102150 -
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03113500 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02588651 -
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
|
Phase 2 | |
| Recruiting |
NCT05978141 -
A Registry for People With T-cell Lymphoma
|
||
| Completed |
NCT01184885 -
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
|
Early Phase 1 | |
| Completed |
NCT02652715 -
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
|
N/A | |
| Recruiting |
NCT04301076 -
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
|
Phase 1 |